The impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn's disease: A single-center paired case-control study

Surgery Today

Volumn 44, Issue 2, 2014, Pages 291-296

  Araki, Toshimitsu ^a   Uchida, Keiichi ^a   Okita, Yoshiki ^a   Fujikawa, Hiroyuki ^a   Inoue, Mikihiro ^a   Ohi, Masaki ^a   Tanaka, Koji ^a   Inoue, Yasuhiro ^a   Mohri, Yasuhiko ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Crohn's disease; Infliximab; Maintenance therapy; Recurrence; Reoperation

Indexed keywords

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CASE-CONTROL STUDIES; COHORT STUDIES; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MAINTENANCE CHEMOTHERAPY; MALE; POSTOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REOPERATION; YOUNG ADULT;

EID: 84895068100     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0538-0     Document Type: Article

References (33)

1. Sachar DB. The problem of postoperative recurrence of Crohn's disease. Med Clin N Am. 1990;74:183-8.
2. Mekhjian HS, Switz DM, Watts HD, Deren JJ, Katon RM, Beman FM. National cooperative Crohn's disease study: factors determining recurrence of Crohn's disease after surgery. Gastroenterology. 1979;77:907-13.
3. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956-63.
4. Cullen G, O'Toole A, Keegan D, Sheahan K, Hyland JM, O'Donoghue DP. Long-term clinical results of ileocecal resection for Crohn's disease. Inflamm Bowel Dis. 2007;13:1369-73.
5. Agwunobi AO, Carlson GL, Anderson ID, Irving MH, Scott NA. Mechanisms of intestinal failure in Crohn's disease. Dis Colon Rectum. 2001;44:1834-7.
6. Binion DG, Theriot KR, Shidham S, Lundeen S, Hatoum O, Lim HJ, et al. Clinical factors contributing to rapid reoperation for Crohn's disease patients undergoing resection and/or strictureplasty. J Gastrointest Surg. 2007;11:1692-8. (discussion 8).
7. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465-73.
8. Sandborn WJ, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology. 2004;127:990-3.
9. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
10. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-13.
11. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-85.
12. Sorrentino D, Terrosu G, Avellini C, Beltrami CA, Bresadola V, Toso F. Prevention of postoperative recurrence of Crohn's disease by infliximab. Eur J Gastroenterol Hepatol. 2006;18:457-9.
13. Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med. 2007;167:1804-7.
14. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009;136:441-50.
15. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the working party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
16. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Impact of surgery for Crohn's disease on health-related quality of life. Am J Gastroenterol. 2000;95:177-82.
17. Pastore RL, Wolff BG, Hodge D. Total abdominal colectomy and ileorectal anastomosis for inflammatory bowel disease. Dis Colon Rectum. 1997;40:1455-64.
18. Yazdanpanah Y, Klein O, Gambiez L, Baron P, Desreumaux P, Marquis P, et al. Impact of surgery on quality of life in Crohn's disease. Am J Gastroenterol. 1997;92:1897-900.
19. Borley NR, Mortensen NJ, Jewell DP. Preventing postoperative recurrence of Crohn's disease. Br J Surg. 1997;84:1493-502.
20. Lock MR, Farmer RG, Fazio VW, Jagelman DG, Lavery IC, Weakley FL. Recurrence and reoperation for Crohn's disease: the role of disease location in prognosis. N Engl J Med. 1981;304:1586-8.
21. Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg. 1991;214:230-8. discussion 8-40.
22. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14:309-17.
23. Sorensen VZ, Olsen BG, Binder V. Life prospects and quality of life in patients with Crohn's disease. Gut. 1987;28:382-5.
24. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55(Suppl 1):i36-58.
25. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-35.
26. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis. 2009;15:1460-6.
27. Tanaka S, Matsuo K, Sasaki T, Nakano M, Sakai K, Beppu R, et al. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed? Hepatogastroenterology. 2010;57:3-7.
28. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98-103.
29. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-30.
30. Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg: Off J Soc Surg Aliment Tract. 2010;14:1859-66.
31. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19:749-54.
32. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-83.
33. Regueiro M, El-Hachem S, Kip KE, Schraut W, Baidoo L, Watson A, et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease. Dig Dis Sci. 2011;56:3610-5.